Common Contracts
1 similar null contracts
ContractDecember 23rd, 2019
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally- Acting Pan-Janus Kinase (JAK) Inhibitor Program
ContractDecember 23rd, 2019
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally- Acting Pan-Janus Kinase (JAK) Inhibitor Program
